Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia

Leukemia

Volumn 25, Issue 8, 2011, Pages 1365-1368

  Blink, M ^a   Buitenkamp, T D ^a   Van Den Heuvel Eibrink, M M ^a   Danen Van Oorschot, A A ^a   De Haas, V ^b   Reinhardt, D ^c   Klusmann, J H ^c   Zimmermann, M ^c   Devidas, M ^d   Carroll, A J ^e   Basso, G ^f   Pession, A ^g   Hasle, H ^h   Pieters, R ^a,b   Rabin, K R ⁱ   Izraeli, S ^j,k   Zwaan, C M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j SHEBA MEDICAL CENTER   (Israel)

^k TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DOWN SYNDROME; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC DISORDER; HUMAN; INFANT; LETTER; LEUKEMIA; MALE; MYELOID LEUKEMIA; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TRANSIENT LEUKEMIA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; HUMANS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; LEUKEMIA, MYELOID; LEUKOCYTE COUNT; MALE; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS;

EID: 80051795878     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.86     Document Type: Letter

References (9)

1. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2001;2:429-436. (Pubitemid 33585947)
2. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005;19:1355-1360. (Pubitemid 41136328)
3. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005;5:11-20. (Pubitemid 40052321)
4. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005;106:4043-4049. (Pubitemid 41775907)
5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397. (Pubitemid 40544655)
6. Klusmann JH, Reinhardt D, Hasle H, Kaspers GJ, Creutzig U, Hahlen K et al. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. Leukemia 2007;21:1584-1587. (Pubitemid 46965309)
7. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484-1492.
8. Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009;144:930-932.
9. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009;106:9414-9418.